The prevalence of CAR-positive T cells in patient-derived tissue sections, observed metabolic and proliferative shifts in the tumor and its microenvironment, and immune checkpoint analysis provide insights into post-CAR T secondary cancers and highlight tools that may guide future targeted therapies.
Jia-Jye Lee, Peirong Hu, Kun Luo et al.· iScience· 0 citations
The ICOS domain promotes trogocytosis and fratricide, explaining the poor persistence and function of ICOS CAR-T cells observed in this trial and raise significant caution for using CAR constructs that rely on ICOS for CAR activation.
Yongxia Wu, Allison Pugel, Katie A. Palen et al.· Journal of Immunology· 0 citations
A trispecific CAR targeting CD19, CD20, and CD22 with OX40 co-stimulatory domain with overall response rate was 50%, including complete responses in 83% of lymphoma patients, and one-year overall survival rate was 61%, with durable remissions observed in lymphoma.
S. Vasu, N. Denlinger, No-Joon Song et al.· Blood Cancer Discovery· 0 citations
Compared to the standard 7-day method, the 3-day approach resulted in expression of genes associated with a more stem-like phenotype while reducing manufacturing time and cost, and may provide a practical alternative for decentralized CAR T-cell manufacturing, particularly in resource-limited settings.
Isabella Vignola, M. Procházková, L. Shao et al.· Journal of Translational Med...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
